Myelofibrosis screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Myelofibrosis}}
{{Myelofibrosis}}
{{CMG}}{{AE}}{{SR}}
{{CMG}}{{AE}}{{SR}}{{Sab}}


==Overview==
==Overview==
There is insufficient evidence to recommend routine screening for myelofibrosis and there is no screening test currently available for the disease. Routine blood work can be used to check the blood cell counts which can further warrant a bone marrow biopsy.
There is insufficient [[evidence]] to recommend routine [[screening]] for [[myelofibrosis]] and there is no [[screening test]] currently available for the [[disease]]. Routine [[blood]] work can be used to check the [[blood cell]] counts which can further warrant a [[bone marrow biopsy]].


==Screening==
==Screening==
*There is insufficient evidence to recommend routine screening for myelofibrosis.
*There is insufficient [[evidence]] to recommend routine [[screening]] for [[myelofibrosis]].
*Blood cell counts can be determined and monitored for any irregularity which can then further warrant a bone marrow biopsy.
*[[Blood cell]] counts can be determined and monitored for any irregularity which can then further warrant a [[bone marrow biopsy]].
*According to 2008 WHO classification of myeloproliferative neoplasms, JAK2<sup>V617F</sup> is the most prevalent mutation with approximately 60% of the primary myelofibrosis (PMF) patients carrying this muatation. This trend is followed in frequency by the mutations in myeloproliferative leukemia virus (MPL) and calreticulin (CALR) genes.<ref name="pmid29426921">{{cite journal |vauthors=Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A |title=The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion |journal=Blood Cancer J |volume=8 |issue=2 |pages=15 |date=February 2018 |pmid=29426921 |pmc=5807384 |doi=10.1038/s41408-018-0054-y |url=}}</ref><ref name="pmid15858187">{{cite journal |vauthors=Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC |title=A gain-of-function mutation of JAK2 in myeloproliferative disorders |journal=N. Engl. J. Med. |volume=352 |issue=17 |pages=1779–90 |date=April 2005 |pmid=15858187 |doi=10.1056/NEJMoa051113 |url=}}</ref><ref name="pmid19357394">{{cite journal |vauthors=Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD |title=The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes |journal=Blood |volume=114 |issue=5 |pages=937–51 |date=July 2009 |pmid=19357394 |doi=10.1182/blood-2009-03-209262 |url=}}</ref>
*According to 2008 [[World Health Organization|World Health Organization (WHO)]] classification of [[Myeloproliferative neoplasm|myeloproliferative neoplasms]], JAK2<sup>V617F</sup> is the most [[Prevalence|prevalent]] [[mutation]] with approximately 60% of the [[Primary myelofibrosis|primary myelofibrosis (PMF)]] [[Patient|patients]] carrying this [[mutation]]. This trend is followed in frequency by the [[Mutation|mutations]] in [[Myeloproliferative leukemia virus oncogene|myeloproliferative leukemia virus (MPL)]] and [[Calreticulin|calreticulin (CALR)]] [[Gene|genes]].<ref name="pmid29426921">{{cite journal |vauthors=Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A |title=The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion |journal=Blood Cancer J |volume=8 |issue=2 |pages=15 |date=February 2018 |pmid=29426921 |pmc=5807384 |doi=10.1038/s41408-018-0054-y |url=}}</ref><ref name="pmid15858187">{{cite journal |vauthors=Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC |title=A gain-of-function mutation of JAK2 in myeloproliferative disorders |journal=N. Engl. J. Med. |volume=352 |issue=17 |pages=1779–90 |date=April 2005 |pmid=15858187 |doi=10.1056/NEJMoa051113 |url=}}</ref><ref name="pmid19357394">{{cite journal |vauthors=Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD |title=The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes |journal=Blood |volume=114 |issue=5 |pages=937–51 |date=July 2009 |pmid=19357394 |doi=10.1182/blood-2009-03-209262 |url=}}</ref>
*Patients can be screened for the above mentioned mutations based on this data.
*[[Patient|Patients]] can be [[Screening|screened]] for the above mentioned [[Mutation|mutations]] based on this data.


==References==
==References==

Latest revision as of 20:55, 18 December 2018

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis screening

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis screening

CDC on Myelofibrosis screening

Myelofibrosis screening in the news

Blogs on Myelofibrosis screening

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]Sabawoon Mirwais, M.B.B.S, M.D.[3]

Overview

There is insufficient evidence to recommend routine screening for myelofibrosis and there is no screening test currently available for the disease. Routine blood work can be used to check the blood cell counts which can further warrant a bone marrow biopsy.

Screening

References

  1. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A (February 2018). "The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion". Blood Cancer J. 8 (2): 15. doi:10.1038/s41408-018-0054-y. PMC 5807384. PMID 29426921.
  2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (April 2005). "A gain-of-function mutation of JAK2 in myeloproliferative disorders". N. Engl. J. Med. 352 (17): 1779–90. doi:10.1056/NEJMoa051113. PMID 15858187.
  3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD (July 2009). "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes". Blood. 114 (5): 937–51. doi:10.1182/blood-2009-03-209262. PMID 19357394.

Template:WH Template:WS